A double-blind evaluation of skin test suppression produced by two doses of terfenadine

Eric W. Bantz, William K. Dolen, Harold S. Nelson

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

For some patients, terfenadine, in the currently recommended dose of 60 mg twice daily (bid), may be only modestly effective in the treatment of allergic rhinitis. In a double-blind placebo-controlled crossover study of 12 patients, a larger dose (300 mg bid) was evaluated for its suppression of titrated skin tests to histamine and compound 48/80 to determine whether this regimen might result in greater suppression while it maintained the freedom from side effects of the presently recommended dose. In seven patients, skin test suppression by these two doses of terfenadine, each administered for 3 days, was compared to that produced in an earlier study by 3 days of treatment with chlorpheniramine (8 mg three times a day). The 300 mg bid terfenadine regimen produced significantly greater skin test suppression (p < 0.05) than the currently recommended 60 mg bid dose. There was no significant difference in side effects between the two doses, and neither active treatment regimen produced more side effects than placebo treatment. Both doses of terfenadine suppressed cutaneous reactivity significantly more than had chlorpheniramine. It is concluded that the presently recommended dose of terfenadine produces submaximal skin test suppression and that further studies are needed to investigate the clinical efficacy and safety of larger doses of terfenadine in the treatment of allergic rhinitis.

Original languageEnglish (US)
Pages (from-to)99-103
Number of pages5
JournalThe Journal of Allergy and Clinical Immunology
Volume80
Issue number1
DOIs
StatePublished - Jan 1 1987

Fingerprint

Terfenadine
Skin Tests
Chlorpheniramine
p-Methoxy-N-methylphenethylamine
Therapeutics
Placebo Effect
Cross-Over Studies
Histamine
Placebos
Safety
Skin

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

A double-blind evaluation of skin test suppression produced by two doses of terfenadine. / Bantz, Eric W.; Dolen, William K.; Nelson, Harold S.

In: The Journal of Allergy and Clinical Immunology, Vol. 80, No. 1, 01.01.1987, p. 99-103.

Research output: Contribution to journalArticle

@article{57a7aaa8dab847d8bfbf9853eb122c72,
title = "A double-blind evaluation of skin test suppression produced by two doses of terfenadine",
abstract = "For some patients, terfenadine, in the currently recommended dose of 60 mg twice daily (bid), may be only modestly effective in the treatment of allergic rhinitis. In a double-blind placebo-controlled crossover study of 12 patients, a larger dose (300 mg bid) was evaluated for its suppression of titrated skin tests to histamine and compound 48/80 to determine whether this regimen might result in greater suppression while it maintained the freedom from side effects of the presently recommended dose. In seven patients, skin test suppression by these two doses of terfenadine, each administered for 3 days, was compared to that produced in an earlier study by 3 days of treatment with chlorpheniramine (8 mg three times a day). The 300 mg bid terfenadine regimen produced significantly greater skin test suppression (p < 0.05) than the currently recommended 60 mg bid dose. There was no significant difference in side effects between the two doses, and neither active treatment regimen produced more side effects than placebo treatment. Both doses of terfenadine suppressed cutaneous reactivity significantly more than had chlorpheniramine. It is concluded that the presently recommended dose of terfenadine produces submaximal skin test suppression and that further studies are needed to investigate the clinical efficacy and safety of larger doses of terfenadine in the treatment of allergic rhinitis.",
author = "Bantz, {Eric W.} and Dolen, {William K.} and Nelson, {Harold S.}",
year = "1987",
month = "1",
day = "1",
doi = "10.1016/S0091-6749(87)80198-7",
language = "English (US)",
volume = "80",
pages = "99--103",
journal = "Journal of Allergy and Clinical Immunology",
issn = "0091-6749",
publisher = "Mosby Inc.",
number = "1",

}

TY - JOUR

T1 - A double-blind evaluation of skin test suppression produced by two doses of terfenadine

AU - Bantz, Eric W.

AU - Dolen, William K.

AU - Nelson, Harold S.

PY - 1987/1/1

Y1 - 1987/1/1

N2 - For some patients, terfenadine, in the currently recommended dose of 60 mg twice daily (bid), may be only modestly effective in the treatment of allergic rhinitis. In a double-blind placebo-controlled crossover study of 12 patients, a larger dose (300 mg bid) was evaluated for its suppression of titrated skin tests to histamine and compound 48/80 to determine whether this regimen might result in greater suppression while it maintained the freedom from side effects of the presently recommended dose. In seven patients, skin test suppression by these two doses of terfenadine, each administered for 3 days, was compared to that produced in an earlier study by 3 days of treatment with chlorpheniramine (8 mg three times a day). The 300 mg bid terfenadine regimen produced significantly greater skin test suppression (p < 0.05) than the currently recommended 60 mg bid dose. There was no significant difference in side effects between the two doses, and neither active treatment regimen produced more side effects than placebo treatment. Both doses of terfenadine suppressed cutaneous reactivity significantly more than had chlorpheniramine. It is concluded that the presently recommended dose of terfenadine produces submaximal skin test suppression and that further studies are needed to investigate the clinical efficacy and safety of larger doses of terfenadine in the treatment of allergic rhinitis.

AB - For some patients, terfenadine, in the currently recommended dose of 60 mg twice daily (bid), may be only modestly effective in the treatment of allergic rhinitis. In a double-blind placebo-controlled crossover study of 12 patients, a larger dose (300 mg bid) was evaluated for its suppression of titrated skin tests to histamine and compound 48/80 to determine whether this regimen might result in greater suppression while it maintained the freedom from side effects of the presently recommended dose. In seven patients, skin test suppression by these two doses of terfenadine, each administered for 3 days, was compared to that produced in an earlier study by 3 days of treatment with chlorpheniramine (8 mg three times a day). The 300 mg bid terfenadine regimen produced significantly greater skin test suppression (p < 0.05) than the currently recommended 60 mg bid dose. There was no significant difference in side effects between the two doses, and neither active treatment regimen produced more side effects than placebo treatment. Both doses of terfenadine suppressed cutaneous reactivity significantly more than had chlorpheniramine. It is concluded that the presently recommended dose of terfenadine produces submaximal skin test suppression and that further studies are needed to investigate the clinical efficacy and safety of larger doses of terfenadine in the treatment of allergic rhinitis.

UR - http://www.scopus.com/inward/record.url?scp=0023189616&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023189616&partnerID=8YFLogxK

U2 - 10.1016/S0091-6749(87)80198-7

DO - 10.1016/S0091-6749(87)80198-7

M3 - Article

VL - 80

SP - 99

EP - 103

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

SN - 0091-6749

IS - 1

ER -